Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments
Published: 06 December 2021
Part 2 | Session 1 Current State of STEMI Care Dan Burkhoff, Steven Yakubov, Andreas Schäfer, Richard Schatz
Part 2 | Session 2 Evolution of STEMI Treatment Dan Burkhoff, Richard Schatz, Steven Yakubov, Andreas Schäfer
Part 2 | Session 3 SSO2 Mechanism of Action Richard Schatz, Dan Burkhoff, Steven Yakubov, Andreas Schäfer
Part 2 | Session 4 Clinical Results of SSO2 Therapy with Case Presentation Steven Yakubov, Dan Burkhoff, Andreas Schäfer, Richard Schatz
Part 2 | Session 5 Case Presentation by Dr A Schäfer Andreas Schäfer, Dan Burkhoff, Steven Yakubov, Richard Schatz
Part 2 | Session 6 Questions and Answers Dan Burkhoff, Richard Schatz, Steven Yakubov, Andreas Schäfer
Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.
During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.
- Understand how SSO2 Therapy works
- Hear about trends in STEMI treatment
- Explore the role of microvascular obstruction and infarct size in outcomes
- Understand the science behind SSO2 Therapy
This series is designed for the entire cardiology community:
- Interventional Cardiologists
- Clinical Fellows and Trainees
More from this programme
Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment
SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders
Infarct Size, Microvascular Obstruction and Outcomes in STEMI: An Expert Panel Discussion
Assistant Professor and Interventional Cardiologist
Dr Nadia Sutton is an Assistant Professor, interventional cardiologist and vascular biologist in the Division of Cardiovascular Medicine and the Frankel Cardiovascular Center at University of Michigan, Michigan, US.
Suzanne de Waha
Dr Suzanne de Waha works at University Heart Center, Luebeck, DE.
Her main focus is acute myocardial infarction (STEMI + NSTEMI), cardiac imaging including CMR, cardiogenic shock, assist devices, interventional cardiology and structural heart disease including TAVI.
Dr de Waha has >150 publications in peer-reviewed, international high-ranked journals.
Dr Dan Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation, New York, US. Dr Burkhoff's interest include cardiovascular modelling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices. He is also author of Harvi, an interactive simulation-based application for teaching and researching on ventricular mechanics and hemodynamics.
Dr Babar Basir is an Interventional Cardiologist at the Henry Ford Hospital in Detroit, Michigan, US.
Dr Basir specialises in the treatment of complex heart blockage with minimally invasive techniques using balloons and stents. He is a national leader in the treatment of cardiogenic shock and lectures around the world on the use of temporary heart pumps when the heart is failing.
Senior Consulting Cardiologist
Dr Jay Traverse is a senior consulting cardiologist at Minneapolis Heart Institute, Minnesota, US. He is also the Director of Research at MHIF and an Associate Professor of Medicine at the University of Minnesota School of Medicine, Minnesota, US.
His special interests include interventional cardiology, stem cell therapy, biomaterials, and ischemia/reperfusion injury.